drugset / Trial / NCT00330850

An Efficacy Study of a Single Dose Treatment of PRO-513 for Subjects Suffering a Migraine Attack

NCT00330850 ↗

Phase 3 Completed 650 enrolled ProEthic Pharmaceuticals
RandomizedDouble-blindTreatment

Summary

The purpose of the study is to show the efficacy of a single dose of PRO-513 for treating subjects suffering moderate pain form a migraine attack, with or without aura. The study is also intended to show the effectiveness of PRO-513 for associated symptoms of nausea, photophobia, and phonophobia due to a migraine attack.

Timeline

Start
2006-05
Primary completion
—
Completion
2006-12

Drugs

EvaluationDrugModalityDoseRoute
Subject PRO-513 Unknown — —